这篇文章不错，转发给_老虎社区_美港股上老虎

这篇文章不错，转发给大家看看

Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":316318661890320,"tweetId":"316318661890320","gmtCreate":1718252524724,"gmtModify":1718252526217,"author":{"id":4176027058679032,"idStr":"4176027058679032","authorId":4176027058679032,"authorIdStr":"4176027058679032","name":"Loongs","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","htmlText":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/316318661890320","repostId":2443511640,"repostType":2,"repost":{"id":"2443511640","pubTimestamp":1718228721,"share":"https://www.laohu8.com/m/news/2443511640?lang=&edition=full","pubTime":"2024-06-13 05:45","market":"us","language":"en","title":"Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2443511640","media":"Zacks","summary":"Pfizer  closed the latest trading day at $27.66, indicating a -1.32% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.Coming into today, shares of the drugmaker had lost 1.23% in the past month. In that same time, the Medical sector gained 2.46%, while the S&P 500 gained 3.11%.The upcoming earnings release of Pfizer will be of great interest to investors. The company is forecasted to report an EPS of $0.45, showcasing a 32.84% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.21 billion, indicating a 3.72% increase compared to the same quarter of the previous year.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rat","content":"<html><body><p>Pfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous session's end. The stock trailed the S&amp;P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.</p>\n<p>Coming into today, shares of the drugmaker had lost 1.23% in the past month. In that same time, the Medical sector gained 2.46%, while the S&amp;P 500 gained 3.11%.</p>\n<p>The upcoming earnings release of Pfizer will be of great interest to investors. The company is forecasted to report an EPS of $0.45, showcasing a 32.84% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.21 billion, indicating a 3.72% increase compared to the same quarter of the previous year.</p>\n<p>For the full year, the Zacks Consensus Estimates are projecting earnings of $2.38 per share and revenue of $60.66 billion, which would represent changes of +29.35% and +3.7%, respectively, from the prior year.</p>\n<p>Investors should also take note of any recent adjustments to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.</p>\n<p>Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.</p>\n<p>The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.63% lower. Pfizer is holding a Zacks Rank of #3 (Hold) right now.</p>\n<p>From a valuation perspective, Pfizer is currently exchanging hands at a Forward P/E ratio of 11.8. For comparison, its industry has an average Forward P/E of 14.38, which means Pfizer is trading at a discount to the group.</p>\n<p>Meanwhile, PFE's PEG ratio is currently 1.1. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.76 based on yesterday's closing prices.</p>\n<p>The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 149, this industry ranks in the bottom 41% of all industries, numbering over 250.</p>\n<p>The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.</p>\n<p>You can find more information on all of these metrics, and much more, on Zacks.com.</p>\n<p>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report</p>\n<p>Pfizer Inc. (PFE) : Free Stock Analysis Report</p>\n<p>To read this article on Zacks.com click here.</p>\n<p>Zacks Investment Research</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer (PFE) Stock Declines While Market Improves: Some Information for Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-13 05:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-pfe-stock-declines-while-214521244.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-pfe-stock-declines-while-214521244.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462","relate_stocks":{"LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4134":"信息科技咨询与其它服务","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4581":"高盛持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","III":"信息服务","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","ISBC":"投资者银行","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999001176.USD":"United Global Healthcare Acc USD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","BK4007":"制药","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4211":"区域性银行","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念"},"source_url":"https://finance.yahoo.com/news/pfizer-pfe-stock-declines-while-214521244.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2443511640","content_text":"Pfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.\nComing into today, shares of the drugmaker had lost 1.23% in the past month. In that same time, the Medical sector gained 2.46%, while the S&P 500 gained 3.11%.\nThe upcoming earnings release of Pfizer will be of great interest to investors. The company is forecasted to report an EPS of $0.45, showcasing a 32.84% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $13.21 billion, indicating a 3.72% increase compared to the same quarter of the previous year.\nFor the full year, the Zacks Consensus Estimates are projecting earnings of $2.38 per share and revenue of $60.66 billion, which would represent changes of +29.35% and +3.7%, respectively, from the prior year.\nInvestors should also take note of any recent adjustments to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.\nOur research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.\nThe Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.63% lower. Pfizer is holding a Zacks Rank of #3 (Hold) right now.\nFrom a valuation perspective, Pfizer is currently exchanging hands at a Forward P/E ratio of 11.8. For comparison, its industry has an average Forward P/E of 14.38, which means Pfizer is trading at a discount to the group.\nMeanwhile, PFE's PEG ratio is currently 1.1. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.76 based on yesterday's closing prices.\nThe Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 149, this industry ranks in the bottom 41% of all industries, numbering over 250.\nThe Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.\nYou can find more information on all of these metrics, and much more, on Zacks.com.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":430,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/316318661890320"}